Is high oral dose L-arginine intake effective in leukoaraiosis? Preliminary data, study protocol and expert's opinion

Current Aging Science

Volumn 6, Issue 2, 2013, Pages 170-177

  Calabró, Rocco Salvatore ^a   Gervasi, Giuseppe ^a   Baglieri, Annalisa ^a   Furnari, Anna ^a   Marino, Silvia ^a   Bramanti, Placido ^a  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Cognitive decline; Gait imbalance; L arginine; Leukoaraiosis; Magnetic resonance; Neuropsychological assessment

Indexed keywords

ARGININE;

AGED; AMNESIA; ARTICLE; CASE REPORT; COGNITION; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DOPPLER ECHO; DRUG EFFICACY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GAIT; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; LEUKOARAIOSIS; MALE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; WHITE MATTER LESION; BRAIN CORTEX ATROPHY; BRAIN FUNCTION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DOPPLER ECHOCARDIOGRAPHY; DRUG MEGADOSE; DRUG WITHDRAWAL; NAUSEA; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT REFUSAL;

EID: 84882785203     PISSN: 18746098     EISSN: 18746128     Source Type: Journal    
DOI: 10.2174/1874609811306020005     Document Type: Article

References (59)

1. Leys D, Englund E, Del Ser T, et al. White matter changes in stroke patients. Relationship with stroke subtype and outcome. Eur Neurol 1999; 42(2): 67-75.
2. Wong TY, Klein R, Sharrett AR, et al. Cerebral white matter lesions, retinopathy, and incident clinical stroke. JAMA 2002; 288: 67-74.
3. Inzitari D, Cadelo M, Marranci ML, Pracucci G, Pantoni L. Vascular deaths in elderly neurological patients with leukoaraiosis. J Neurol Neurosurg Psychiatry 1997; 62: 177-181.
4. Palumbo V, Boulanger JM, Hill MD, Inzitari D, Buchan AM; CASES Investigators. Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke. Neurology 2007; 68: 1020-1024.
5. Arsava EM, Rahman R, Rosand J, et al. Severity of leukoaraiosis correlates with clinical outcome after ischemic stroke. Neurology 2009; 72: 1403-1410.
6. Ay H, Arsava EM, Rosand J, et al. Severity of leukoaraiosis and susceptibility to infarct growth in acute stroke. Stroke 2008; 39: 1409-1413.
7. Görner A, Lemmens R, Schrooten M, Thijs V. Is leukoaraiosis on CT an accurate surrogate marker for the presence of microbleeds in acute stroke patients? J Neurol 2007; 254: 284-289.
8. Buyck JF, Dufouil C, Mazoyer B, et al. Cerebral white matter lesions are associated with the risk of stroke but not with other vascular events: the 3-City Dijon Study. Stroke 2009; 40: 2327-2331.
9. Prins ND, van Dijk EJ, den Heijer T, et al. Cerebral white matter lesions and the risk of dementia. Arch Neurol 2004; 61:1531-1534.
10. Briley DP, Haroon S, Sergent SM, Thomas S. Does leukoaraiosis predict morbidity and mortality? Neurology 2000; 54: 90-94.
11. Szolnoki Z. Pathomechanism of laukoarariosis: A Molecular Bridge Between the Genetic, Biochemical, and Clinical Processes (a Mitochondrial Hypothesis). Neuromol Med 2007; 9: 21-34.
12. Wardlaw JM, Sandercock PA, Dennis MS, Starr J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke 2003; 34: 806-812.
13. Turner ST, Fornage M. Genetics of leukoaraiosis. J Stroke Cerebrovasc Dis 2002; 11: 241-251.
14. White RP, Deane C, Vallance P, Markus HS. Nitric oxide synthase inhibition in humans reduces cerebral blood flow but not the hyperaemic response to hypercapnia. Stroke 1998; 29: 467-472.
15. Böger RH and Bode-Böger SM. The clinical pharmacology of LArginine. Annu Rev Pharmacol Toxicol 2001; 41: 79-99.
16. Coman D, Yaplito-Lee J, Boneh A. New indications and controversies in arginine therapy. Clin Nutr 2008; 27: 489-496.
17. Oomen CM, van Erk MJ, Feskens EJ, Kok FJ, Kromhout D. Arginine intake and risk of coronary heart disease mortality in erderly men. Arterioscler Thromb Vasc Biol 2000; 20:2134-2139.
18. Böger RH, Bode-Böger SM, Thiele W, Creutzig A, Alexander K, Frölich JC. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 1998; 32:1336-1344.
19. Chen J, Wollman Y, Chernichovsky T, Iaina A, Sofer M, Matzkin H. Effect of oral administration of high-dose nitric oxide donor Larginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study. BJU Int 1999; 63: 220-223.
20. Koga Y, Akita Y, Nishioka J, et al. MELAS and L-arginine therapy. Mitochondrion 2007; 7(1-2): 133-139.
21. Helenius J, Tatlisumak T. Treatment of leukoaraiosis: a futuristic view. Curr Drug Targets 2007; 8: 839-845.
22. Soinne L, Helenius J, Saimanen E, et al. Brain diffusion changes in carotid occlusive disease treated with endarterectomy. Neurology 2003; 61: 1061-1065.
23. Bès A, Orgogozo JM, Poncet M, et al. A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. Eur J Neurol 1999; 6: 313-322.
24. Pantoni L, Carosi M, Amigoni S, Mascalchi M, Inzitari D. A preliminary open trial with nimodipine in patients with cognitive impairment and leukoaraiosis. Clin Neuropharmacol 1996; 19: 497-506.
25. Böger RH. The Pharmacodynamics of L-Arginine. J Nutr 2007; 137: 1650S-1655S.
26. Calabrò RS, Gervasi G, Bramanti P. Does L-arginine supplementation play a role in cerebral small vessels disease? Implication in the treatment of leukoaraiosis. Med Hypotheses 2011; 77: 671-673.
27. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987; 149: 351-356.
28. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002; 17: 479-489.
29. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12: 189-198.
30. Giovagnoli AR, Del Pesce M, Mascheroni S, Simoncelli M, Laiacona M, Capitani E. Trail making test: normative values from 287 normal adult controls. Ital J Neurol Sci 1996;17: 305-309.
31. Venturini R, Lombardo Radice M., Imperiali MG. Il "Color-Word Test" o Test di Stroop Organizzazioni Speciali, Firenze, 1983.
32. Raven JC. Standard progressive matrices-manuale. Organizzazioni Speciali, Firenze, 1981.
33. Berg EA. A simple objective technique for measuring flexibility in thinking. J Gen Psychol 1948; 39: 15-22.
34. Spinnler H, Tognoni G. Standardizzazione e taratura italiana di Test neuropsicologici. Ital J Neurol Sci 1987; (suppl 8): 6.
35. Caffarra P, Vezzadini G, Dieci F, Zonato F, Venneri A. Rey-Osterrieth complex figure: normative values in an Italian population sample. Neurol Sci 2002; 22: 443-447.
36. Novelli G, Papagno C, Capitani E, Laiacona N, Vallar G, Cappa SF. Tre test clinici di ricerca e produzione lessicale. Taratura su soggetti normali. Archivio di Psicologia, Neurologia e Psichiatria 1986; 47: 447-506.
37. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-2314.
38. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
39. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-55.
40. Keith RA, Granger CV, Hamilton BB, Sherwin FS. The functional independence measure: a new tool for rehabilitation. Adv Clin Rehabil 1987; 1: 6-18.
41. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial function. JAMA 1963; 185: 914-919.
42. Lawton MP, Brody EM. Assessment of older people: selfmaintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179-186.
43. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health survey: manual and interpretation guide. Boston, Massachusetts: The Health Institute, New England Medial Center 1997.
44. Pantoni L. Leukoaraiosis: from an ancient term to an actual marker of poor prognosis. Stroke 2008; 39:1401-1413.
45. Pantoni L, Poggesi A, Basile AM, et al. Leukoaraiosis predicts hidden global functioning impairment in nondisabled older people: the LADIS (Leukoaraiosis and Disability in the Elderly) Study. J Am Geriatr Soc 2006; 54:1095-1101.
46. Jokinen H, Kalska H, Ylikoski R, et al. Longitudinal cognitive decline in subcortical ischemic vascular disease--the LADIS Study. Cerebrovasc Dis 2009; 27: 384-391.
47. Inzitari D, Pracucci G, Poggesi A, et al. Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. BMJ 2009; 339: b2477.
48. Welker KM, De Jesus RO, Watson RE, Machulda MM, Jack CR. Altered functional MR imaging language activation in elderly individuals with cerebral leukoaraiosis. Radiology 2012; 265: 222-232.
49. Park K, Nakagawa Y, Kumagai Y, Nagahara M. Leukoaraiosis, a common brain magnetic resonance imaging finding, as a predictor of traffic crashes. PLoS One 2013; 8: e57255.
50. Serra L, Cercignani M, Basile B, et al. White matter damage along the uncinate fasciculus contributes to cognitive decline in AD and DLB. Curr Alzheimer Res 2012; 9: 326-333.
51. Tveiten A, Ljøstad U, Mygland A, Naess H. Leukoaraiosis is associated with short-and long-term mortality in patients with Intracerebral Hemorrhage. J Stroke Cerebrovasc Dis 2013. doi:pii: S1052-3057(13)00023-2.10.1016/j.jstrokecerebrovasdis.2013.01.017.
52. Caprio FZ, Maas MB, Rosenberg NF, et al. Leukoaraiosis on magnetic resonance imaging correlates with worse outcomes after spontaneous intracerebral hemorrhage. Stroke 2013; 44: 642-646.
53. Filippi M, Agosta F, Frisoni GB, et al. Magnetic resonance imaging in Alzheimer's disease: from diagnosis to monitoring treatment effect. Curr Alzheimer Res 2012; 9: 1198-1209.
54. Pimentel AM, Pereira NR, Costa CA, et al. L-arginine-nitric oxide pathway and oxidative stress in plasma and platelets of patients with pre-eclampsia. Hypertens Res 2013; doi: 10.1038/hr.2013.34.
55. Coman D, Yaplito-Lee J, Boneh A. New indications and controversies in arginine therapy. Clin Nutr 2008; 27: 489-496.
56. Wei XM, Yang W, Liu LX, Qi WX. Effects of L-arginine and N_-nitro-L-arginine methylester on learning and memory and _7 nAChR expression in the prefrontal cortex and hippocampus of rats. Neurosci Bull 2013; 29(3): 303-310.
57. Woodard JL, Sugarman MA, Nielson KA, et al. Lifestyle and genetic contributions to cognitive decline and hippocampal structure and function in healthy aging. Curr Alzheimer Res 2012; 9: 436-446.
58. Verdelho A, Madureira S, Ferro JM, et al. Physical activity prevents progression for cognitive impairment and vascular dementia: results from the LADIS (Leukoaraiosis and Disability) study. Stroke 2012; 43: 3331-3335.
59. Kubota M, Sakakihara Y, Mori M, Yamagata T, Momoi-Yoshida M. Beneficial effect of L-arginine for stroke-like episode in MELAS. Brain Dev 2004; 26: 481-483.